Journal article
Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials
SB Coutts, E Berge, BCV Campbell, KW Muir, MW Parsons
International Journal of Stroke | SAGE PUBLICATIONS LTD | Published : 2018
Abstract
Alteplase has been the mainstay of thrombolytic treatment since the National Institutes of Neurological Disorders and Stroke trial was published in 1995. Over recent years, several trials have investigated alternative thrombolytic agents. Tenecteplase, a genetically engineered mutant tissue plasminogen activator, has a longer half-life, allowing single intravenous bolus administration without infusion, is more fibrin specific, produces less systemic depletion of circulating fibrinogen, and is more resistant to plasminogen activator inhibitor compared to alteplase. Tenecteplase is established as the first-line intravenous thrombolytic drug for myocardial infarction, where it has been shown to..
View full abstractGrants
Funding Acknowledgements
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: TEMPO-2 is funded by grants from Heart and stroke foundation of Canada and Canadian Institute of Health Research. ATTEST-2 is funded by a grant from the Stroke Association and British Heart Foundation. TASTE is funded by grants from the National Health and Medical Research Council of Australia, National Stroke Foundation of Australia, and National Heart Foundation of Australia. TWIST is funded by the Norwegian Ministry of Health and Care Services, the National Association for Public Health, British Heart Foundation, and Swiss Heart Foundation. EXTEND-IA TNK II is funded by grants from the National Health and Medical Research Council of Australia and National Heart Foundation of Australia.